News and Media

Ixaka Appoints Karen Miller as Chief Scientific Officer

12/07/2022

London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power…

Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001

27/06/2022

REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…

Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area

21/03/2022

London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…

CELTIC-19 granted Advanced Therapy Medicinal Product classification by European Medicines Agency

08/03/2022

CELTIC-19 – Ixaka’s targeted nanoparticle for CD19 haematological malignancies – has been granted Advanced Therapy Medicinal Product (ATMP) classification by…

Ixaka Expands Management Team with Multiple Appointments

10/02/2022

Nick Robbins-Cherry, ex-Midatech, joins as CFO George O’Rourke, joins as VP & GM Ixaka France, from Novartis Gene Therapy London,…

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

08/09/2021

The positive interim analysis of the efficacy and safety results from the first 30% of enrolled patients evaluated 12 months…

Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit

31/08/2021

CSO, Cecile Bauche, also chairing panel discussion on optimising animal models for cell therapy Five posters covering the application of…

Ixaka appoints Laurent Audoly as a Non-Executive Director

02/08/2021

London, UK, 2 August 2021: Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of…

Ixaka and SomaLogic enter research collaboration to develop bispecific agents for oncology

29/06/2021

Ixaka Ltd and SomaLogic today announce a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will…

Ixaka appoints Christian Hoyer Millar as a Non-Executive Director

19/04/2021

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease,…

Leiden University Medical Center and Ixaka enter collaboration to strengthen knowledge of cell therapy candidate REX-001

30/03/2021

Ixaka Ltd and Leiden University Medical Center (LUMC) today announce a research collaboration to expand understanding of Ixaka’s lead multi-cell…

Ixaka strengthens IP Portfolio for its in vivo gene delivery platform and multi-cell therapy with key European and US patents

08/02/2021

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease,…

Ixaka (formerly Rexgenero) launches as an integrated cell and gene therapy company

18/01/2021

London, UK, 18 January 2021: Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of…

Rexgenero Appoints Sadia L’Baouch as Chief Manufacturing Officer

07/12/2020

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia (CLTI), today announces the appointment of…

Rexgenero Announces Positive Outcome of Independent Data Monitoring Committee Meeting for Phase III Trial for Diabetic Patients with Critical Limb-Threatening Ischaemia

26/10/2020

REX-001 is an autologous cell-based product intended to treat critical limb-threatening ischaemia in diabetic patients Independent Data Monitoring Committee recommended…

Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer

02/07/2020

London, UK, 2 July 2020: Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today…

Rexgenero acquires the key technology and program assets of aratinga.bio SAS Group

22/06/2020

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today announces the acquisition of…

Rexgenero Appoints Huw Jones as a Non-Executive Director

12/02/2020

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today announces that Dr Huw…

Rexgenero Appoints David Horn Solomon as Chairman

10/02/2020

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), today announces…

First UK Clinical Trial Site Open for Recruitment of Diabetic Patients with Chronic Limb-Threatening Ischemia

04/12/2019

Phase III SALAMANDER Trials of Rexgenero’s REX-001 Open and Recruiting Patients at the University Hospital of Wales in Cardiff The…

Rexgenero to Present at the Solebury Trout Private Company Showcase in New York City

19/10/2019

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), announces today…

Rexgenero Shortlisted as a Finalist for Clinical Trial of the Year Lifestars Award

11/09/2019

Rexgenero, a clinical-stage regenerative medicine company pioneering the development of advanced cell-based therapies, has been shortlisted as a finalist for…

Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies

21/08/2019

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia (CLI), welcomes the…

First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava

29/05/2019

Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting The first diabetic patient in the Czech Republic with a…

Rexgenero Successfully Expands Manufacturing of REX-001 through Partnership with German Red Cross Blood Donor Service

28/05/2019

Enables new sites to participate in the European Phase III SALAMANDER trials Rexgenero, a regenerative medicine company developing advanced cell-based…

Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia

24/04/2019

At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona Rexgenero, a regenerative medicine…

Rexgenero’s Lead Product REX-001 Selected for the EUnetHTA Prioritisation List for Joint Assessments

07/01/2019

The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant interest by national…

EMA grants Rexgenero’s lead product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data

30/01/2018

REX-001 is a novel cell therapy for the treatment of Critical Limb Ischemia (CLI), a disease which affects an estimated…

Rexgenero treats first patient in its Rexgenero treats first patient in its Phase III programme with lead product REX-001, a novel cell therapy for the treatment of Critical Limb Ischemia (CLI)

25/01/2018

London, UK, 25th January 2018: Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapies with a focus on…

Rexgenero secures Innovate UK Grant

23/01/2018

London, UK, 23rd January 2018: Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapeutics with a focus on…

Rexgenero Announces the Appointment of Sam MacHour to its Scientific Advisory Board

13/11/2017

London, UK, 13 November 2017: Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapeutics with a focus on…

Rexgenero Announces Formation of Scientific Advisory Board

05/01/2017

Rexgenero Announces Formation of Scientific Advisory Board and Appoints Leading Experts in Cell Therapy, Cardiovascular Diseases and Wound Healing …

Rexgenero receives Rexgenero receives confirmation from the EMA that the design of two confirmatory Phase III clinical trials for Rexmyelocel-T is acceptable

13/10/2016

London, UK. Rexgenero received a Follow-up Scientific Advice letter from the Committee for Medicinal Products for Human Use (CHMP) of…